**EUROPEAN PATENT APPLICATION**

**Application number:** 08171062.6

**Date of filing:** 16.05.2002

**Designated Contracting States:**
- AT
- BE
- CH
- CY
- DE
- DK
- ES
- FI
- FR
- GB
- GR
- IE
- IT
- LU
- MC
- NL
- PT
- SE
- TR

**Designated Extension States:**
- AL
- LT
- LV
- MK
- RO
- SI

**Priority:**
- 18.05.2001 SE 0101772
- 15.11.2001 SE 0103820

**Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:**
- 02733712.0
- 1 395 567

**Applicant:** AstraZeneca AB
151 85 Södertälje (SE)

**Inventors:**
- Brown, William
  Montréal, Québec H4S 1Z9 (CA)
- Hudzik, Thomas
  PO Box 15437
  Wilmington, DE 19850-5437 (US)
- Walpole, Christopher
  St Laurent
  Montréal, Québec H4S 1Z9 (CA)
- Plobeck, Niklas
  151 85, Södertälje (SE)

**Remarks:**
This application was filed on 09-12-2008 as a divisional application to the application mentioned under INID code 62.

**Int Cl.:**
- C07D 295/14 (2006.01)
- A61K 31/495 (2006.01)
- A61P 1/00 (2006.01)
- A61P 25/00 (2006.01)

**Compounds of general formula I**

![Chemical structure](image)

R¹ is selected from any one of phenyl, furanyl, and pyrrolyl, wherein each of phenyl, pyrrolyl, and furanyl may optionally and independently be substituted by 1 or 2 substituents selected from CF₃, methyl, chloro, fluoro, bromo, and iodo;

R² is independently selected from ethyl and isopropyl;

R³ is independently selected from hydrogen and fluoro; and

R⁴ is -NH₂;

or salts thereof or separate enantiomers and salts thereof;

are disclosed and claimed in the present application, as well as separate enantiomers of the compounds and salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain, anxiety and functional gastrointestinal disorders.
Description

Field of the Invention

[0001] The present invention is directed to novel compounds, to a process for their preparation, their use and pharmaceutical compositions comprising the novel compounds. The novel compounds are useful in therapy, and in particular for the treatment of pain, anxiety and functional gastrointestinal disorders.

Background of the Invention

[0002] The \( \delta \) receptor has been identified as having a role in many bodily functions such as circulatory and pain systems. Ligands for the \( \delta \) receptor may therefore find potential use as analgesics, and/or as antihypertensive agents. Ligands for the \( \delta \) receptor have also been shown to possess immunomodulatory activities.

[0003] The identification of at least three different populations of opioid receptors (\( \mu \), \( \delta \) and \( \kappa \)) is now well established and all three are apparent in both central and peripheral nervous systems of many species including man. Analgesia has been observed in various animal models when one or more of these receptors has been activated.

[0004] With few exceptions, currently available selective opioid \( \delta \) ligands are peptidic in nature and are unsuitable for administration by systemic routes. One example of a non-peptidic \( \delta \)-agonist is SNC80 (Bilsky E.J. et al., Journal of Pharmacology and Experimental Therapeutics, 273(1), pp. 359-366 (1995)). There is however still a need for selective \( \delta \)-agonists having not only improved selectivity, but also an improved side-effect profile.

[0005] Thus, the problem underlying the present invention was to find new analgesics having improved analgesic effects, but also with an improved side-effect profile over current \( \mu \) agonists, as well as having improved systemic efficacy.

[0006] Analgesics that have been identified and are existing in the prior art have many disadvantages in that they suffer from poor pharmacokinetics and are not analgesic when administered by systemic routes. Also, it has been documented that preferred \( \delta \) agonist compounds, described within the prior art, show significant convulsive effects when administered systemically.

[0007] We have now found certain compounds that exhibit surprisingly improved properties, i.a. improved \( \delta \)-agonist potency, in vivo potency, pharmacokinetic, bioavailability, in vitro stability and/or lower toxicity.

Outline of the Invention

[0008] The novel compounds according to the present invention are defined by the formula I

\[
\text{I} \quad \text{(1) phenyl;}
\]

\[
\text{R}^1 \text{ is selected from any one of}
\]

\[
\text{wherein}
\]

\[
\text{EP 2 042 495 A1}
\]
(ii) pyridinyl

(iii) thienyl

(iv) furanyl

(v) imidazolyl

(vi) triazolyl

(vii) pyrrolyl

(viii) thiazolyl
wherein each R\textsuperscript{1} heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C\textsubscript{1}–C\textsubscript{6} alkyl, halogenated C\textsubscript{1}–C\textsubscript{6} alkyl, NO\textsubscript{2}, CF\textsubscript{3}, C\textsubscript{1}–C\textsubscript{6} alkoxy, chloro, fluoro, bromo, and iodo;

R\textsuperscript{2} is independently selected from ethyl and isopropyl;

R\textsuperscript{3} is independently selected from hydrogen and fluoro;

R\textsuperscript{4} is independently selected from -OH, -NH\textsubscript{2} and -NHSO\textsubscript{2}R\textsuperscript{5}; and

R\textsuperscript{5} is independently selected from hydrogen, -CF\textsubscript{3} and C\textsubscript{1}–C\textsubscript{6} alkyl, provided that when R\textsuperscript{2} is ethyl and R\textsuperscript{3} is hydrogen then R\textsuperscript{4} cannot be -OH.

The substitutions on the heteroaromatic ring may take place in any position on said ring systems.

When the R\textsuperscript{1} phenyl ring and the R\textsuperscript{1} heteroaromatic ring(s) are substituted, the preferred substituents are selected from any one of CF\textsubscript{3}, methyl, iodo, bromo, fluoro and chloro, of which methyl is most preferred.

A further embodiment of the present invention is thus a compound according to formula I wherein R\textsuperscript{1} is as defined above and each R\textsuperscript{1} phenyl ring and R\textsuperscript{1} heteroaromatic ring may independently be further substituted by a methyl group;

A further embodiment of the present invention is a compound according to figure I wherein R\textsuperscript{1} is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R\textsuperscript{2} is ethyl or isopropyl; R\textsuperscript{3} is hydrogen or fluoro; R\textsuperscript{4} is -NH\textsubscript{2} or -NHSO\textsubscript{2}R\textsuperscript{5}; and R\textsuperscript{5} is C\textsubscript{1}–C\textsubscript{6} alkyl, optionally with 1 or 2 of the preferred substituents on the R\textsuperscript{1} phenyl or R\textsuperscript{1} heteroaromatic ring.

An additional embodiment of the present invention is a compound according to figure I wherein R\textsuperscript{1} is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R\textsuperscript{2} is ethyl or isopropyl; R\textsuperscript{3} is hydrogen; R\textsuperscript{4} is -NHSO\textsubscript{2}R\textsuperscript{5}; and R\textsuperscript{5} is C\textsubscript{1}–C\textsubscript{6} alkyl, optionally with 1 or 2 of the preferred substituents on the R\textsuperscript{1} phenyl or R\textsuperscript{1} heteroaromatic ring.

Other embodiments of the present invention are compounds according to Figure I wherein a) R\textsuperscript{1} is phenyl, pyrrolyl, or furanyl; R\textsuperscript{2} is ethyl or isopropyl; R\textsuperscript{3} is hydrogen or fluoro; and R\textsuperscript{4} is -NH\textsubscript{2}; b) R\textsuperscript{1} is thienyl or imidazolyl; R\textsuperscript{2} is ethyl or isopropyl; R\textsuperscript{3} is hydrogen or fluoro; and R\textsuperscript{4} is -NH\textsubscript{2}; c) R\textsuperscript{1} is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R\textsuperscript{2} is ethyl or isopropyl; R\textsuperscript{3} is hydrogen or fluoro; R\textsuperscript{4} is -NHSO\textsubscript{2}R\textsuperscript{5}; and R\textsuperscript{5} is C\textsubscript{1}–C\textsubscript{6} alkyl; and d) R\textsuperscript{1} is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R\textsuperscript{2} is ethyl or isopropyl; R\textsuperscript{3} is hydrogen or fluoro; R\textsuperscript{4} is -NHSO\textsubscript{2}R\textsuperscript{5}; and R\textsuperscript{5} is C\textsubscript{1}–C\textsubscript{6} alkyl, wherein all embodiments a) to d) may optionally be substituted with 1 or 2 of the preferred substituents on the R\textsuperscript{1} phenyl or R\textsuperscript{1} heteroaromatic ring.

Within the scope of the invention are also separate enantiomers and salts of the compounds of the formula I, including salts of enantiomers. Also within the scope of the present invention are mixtures of the separate enantiomers, such as the racemic mixture, as well as salts of mixtures of separate enantiomers.

Separation of racemic mixtures into separate enantiomers is well known in the art and may be accomplished for example by separation on a suitable chiral chromatography column. Preparation of salts is well known in the art, and may be accomplished for example by mixing a compound of formula I in a suitable solvent with the desired protic acid and isolation by means standard in the art. Salts of compounds of formula I include pharmaceutically acceptable salts and also pharmaceutically unacceptable salts.

The novel compounds of the present invention are useful in therapy, especially for the treatment of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive.

Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.

Compounds of the invention are useful in disease states where degeneration or dysfunction of opioid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds.
of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET).

Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder; urinary incontinence, various mental illnesses, cough, lung oedema, various gastrointestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson’s disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following myocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.

Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.

Also within the scope of the invention is the use of any of the compounds according to the formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.

A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such treatment.

Methods of preparation

The compounds of the present invention can be prepared using the following general procedure.

Preparation of Anilines; Example 1

The compound of formula I wherein R⁴ is -NH₂ is prepared by reacting a compound of the general formula IV

![IV](image)

wherein R² and R³ are as defined in Figure 1 and R⁴ is NO₂, with Boc-piperazine in acetonitrile in the presence of triethylamine under standard conditions, followed by removal of the Boc protection group under standard conditions to give a compound of the Formula V

![V](image)

which is thereafter alkylated under reductive conditions with a compound of the Formula R¹-CHO, followed by reduction of the nitro group using hydrogen and palladium on charcoal to give a compound of the Formula I wherein R⁴ is -NH₂.
Within the scope of the invention are also separate enantiomers and salts of the compounds of the Formula I, including salts of enantiomers. Compounds of Formula I are chiral compounds, with the diarylmethylpiperazine group being the stereogenic center, see Figure I* below.

A further embodiment of the present invention is thus the (-)-enantiomer of a compound according to Formula I, as well as a salt of said compound.

A further embodiment of the present invention is thus the (+)-enantiomer of a compound according to Formula I, as well as a salt of said compound.

EXAMPLES

The invention will now be described in more detail by the following Examples, which are not to be construed as limiting the invention.

Intermediate 1: 4-[hydroxy(3-nitrophenyl)methyl]-N,N-diisopropylbenzamide.

N,N-Diisopropyl-4-iodobenzamide (6.0 g, 18 mmol) was dissolved in THF (200 mL) and cooled to -78 °C under nitrogen atmosphere. n-BuLi (14 mL, 1.3 M solution in hexane, 18 mmol) was added dropwise during 10 min at -65 to -78 °C. After addition of n-BuLi, the solution was cannulated into a solution of 3-nitrobenzaldehyde (2.7 g, 18 mmol) in toluene/THF (approx. 1:1, 100 mL) at -78 °C. Workup and chromatography gave for intermediate 1 (2.4 g, 37%).

$^1$H NMR (CDCl$_3$) δ 1.1-1.7 (m, 12H), 3.90 (d, J = 3.5 Hz, 1H), 3.4-3.9 (m, 2H), 5.91 (s, J = 3.5Hz, 1H), 7.27, 7.35 (2d, J = 8Hz,

[0031] Intermediate 1 (2.4 g, 6.7 mmol) was dissolved in dry CH$_2$Cl$_2$ (50 mL) and treated with SOBr$_2$ (0.88 mL, 11 mmol) at 0 to 25 °C for 30 min. Neutralization with KHCO$_3$ (aq.) and drying (K$_2$CO$_3$) of the organic phase was followed by solvent evaporation in vacuo. The residue and Et$_3$N (1.8 mL, 13 mmol) was dissolved in MeCN (50 mL) and stirred with Boc-piperazine (2.1 g, 11 mmol) at 25 °C for 12 h. The mixture was concentrated in vacuo and chromatographed on silica (0 to 50% EtOAc in heptane). The resulting product was treated with TFA in CH$_2$Cl$_2$ (1:1), concentrated in vacuo, extracted CH$_2$Cl$_2$/ K$_2$CO$_3$ (aq.), dried (K$_2$CO$_3$) and evaporated in vacuo to give Intermediate 2 (2.83 g, 81%). MS (ES) 425.23 (MH$^+ $).

Example 1: 4-[(3-Amino-phenyl)-1-(4-benzyl-piperazin-1-yl)-methyl]-N,N-diisopropyl-benzamide.

[0032] Intermediate 2 (0.40 g, 0.94 mmol) and triethylamine (0.20 mL, 1.4 mmol) were dissolved in ACN (10 mL). Benzyl bromide (0.14 mL, 1.1 mmol) was added with stirring at 25 °C. Reaction with benzyl bromide was followed by hydrogenation (H$_2$, 40 psi) with 10% Pd/C (50 mg) in EtOH (25 mL) and 2 N HCl (1.2 mL, 2.4 mmol) for 2 h. The solution was concentrated and purified by reverse phase chromatography (LiChroprep RP-18, 10-80 % MeCN in water, 0.1 % TFA). Free base was obtained after extraction with CH$_2$Cl$_2$/K$_2$CO$_3$ (aq.), drying (K$_2$CO$_3$) and evaporation in vacuo. Treatment with boron tribromide (4 eq., 1M solution in CH$_2$Cl$_2$) in CH$_2$Cl$_2$ at -78 °C, addition of water, concentration in vacuo and reverse phase chromatography gave Example 1 (0.20 g, 30%) as the trifluoroacetate. MS (ES) 485.40 (MH$^+ $).

Example 2: 4-[[3-aminophenyl](4-benzyl-1-piperazinyl)methyl]-N,N-diethylbenzamide.

[0033] N,N-diethyl-4-[[3-nitrophenyl](1-piperazinyl)methyl]benzamide (prepared analogous to intermediate (2) in Scheme 1) (1.7g g, 4.3 mmol) and triethylamine (1.2 mL, 8.6 mmol) was dissolved in MeCN (10 mL). Benzyl bromide (0.56 mL, 4.7 mmol) was added with stirring at 25 °C. After 12 h the solution was concentrated in vacuo. Extraction (CH$_2$Cl$_2$/K$_2$CO$_3$(aq)) and purification by chromatography on silica gave the benzylated product (1.4 g, 2.9 mmol). Hydrogenation (H$_2$, 40 psi) with 10% Pd/C (100 mg) in EtOH (25 mL) and 2 N HCl (2.5 mL, 5 mmol) for 4 h was followed by concentration in vacuo and reverse phase chromatography to give the title compound as the triis-(trifluoroacetate) (2.83 g, 81%). MS (ES) 457.26 (MH$^+ $). IR (NaCl) 3422, 1672, 1603, 1458, 1209, 1133 (cm$^{-1}$).

Scheme 2: Preparation of Example 2

Example 2: 4-[(3-aminophenyl)(4-benzyl-1-piperazinyl)methyl]-N,N-diethylbenzamide.

[0034] The novel compounds according to the present invention may be administered orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracically, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.

[0035] A preferred route of administration is orally, intravenously or intramuscularly.

[0036] The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient.

4H, 7.51 (m, 1H), 7.71 (m, 1H), 8.13 (m, 1H), 8.30 (s, 1H).

and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.

[0037] For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

[0038] A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

[0039] In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

[0040] For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.

[0041] Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

[0042] Salts include, but are not limited to pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts within the scope of the present invention include: acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium acetate, camysylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glucosamine, glucuronate, glutamate, glycolylarsanilate, hexylresorinate, hydrabamine, hydrobromide, hydrochloride, hydroxypropionate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylchloride, methylisobutyl, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, triethiodide, benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, megulmine, procaine, aluminium, calcium, lithium, magnesium, potassium, sodium, and zinc. Examples of pharmaceutically unacceptable salts within the scope of the present invention include: hydroiodide, perchlorate, and tetrafluoroborate. Pharmaceutically unacceptable salts could be of use because of their advantageous physical and/or chemical properties, such as crystallinity.

[0043] Preferred pharmaceutically acceptable salts are the hydrochlorides, sulfates and bitartrates. The hydrochloride and sulfate salts are particularly preferred.

[0044] The term composition is intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.

[0045] Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

[0046] Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration. Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polynethylene glycol solution.

[0047] Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

[0048] Preferably the pharmaceutical compositions is in unit dosage form. In such form, the composition is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.

**BIOLOGICAL EVALUATION**

**In vitro model**

**Cell culture**

[0049] A. Human 293 S cells expressing cloned human μ, δ, and κ receptors and neomycin resistance were grown in suspension at 37°C and 5% CO₂ in shaker flasks containing calcium-free DMEM10% FBS, 5% BCS, 0.1% Pluronic F-68, and 600 μg/ml geneticin.

B. Mouse and rat brains were weighed and rinsed in ice-cold PBS (containing 2.5mM EDTA, pH 7.4). The brains
were homogenized with a polytron for 15 sec (mouse) or 30 sec (rat) in ice-cold lysis buffer (50mM Tris, pH 7.0, 2.5mM EDTA, with phenylmethylsulfonyl fluoride added just prior use to 0.5mM from a 0.5M stock in DMSO: ethanol).

Membrane preparation

[0050] Cells were pelleted and resuspended in lysis buffer (50 mM Tris, pH 7.0, 2.5 mM EDTA, with PMSF added just prior to use to 0.1 mM from a 0.1 M stock in ethanol), incubated on ice for 15 min, then homogenized with a polytron for 30 sec. The suspension was spun at 1000g (max) for 10 min at 4°C. The supernatant was saved on ice and the pellets resuspended and spun as before. The supernatants from both spins were combined and spun at 46,000 g(max) for 30 min. The pellets were resuspended in cold Tris buffer (50 mM Tris/Cl, pH 7.0) and spun again. The final pellets were resuspended in membrane buffer (50 mM Tris, 0.32 M sucrose, pH 7.0). Aliquots (1 ml) in polypropylene tubes were frozen in dry ice/ethanol and stored at -70°C until use. The protein concentrations were determined by a modified Lowry assay with sodium dodecyl sulfate.

Binding assays

[0051] Membranes were thawed at 37°C, cooled on ice, passed 3 times through a 25-gauge needle, and diluted into binding buffer (50 mM Tris, 3 mM MgCl$_2$, 1 mg/ml BSA (Sigma A-7888), pH 7.4, which was stored at 4°C after filtration through a 0.22 m filter, and to which had been freshly added 5 µg/ml aprotinin, 10 µM bestatin, 10 µM diprotin A, no DTT). Aliquots of 100 µl were added to iced 12x75 mm polypropylene tubes containing 100 µl of the appropriate radioligand and 100 µl of test compound at various concentrations. Total (TB) and nonspecific (NS) binding were determined in the absence and presence of 10 µM naloxone respectively. The tubes were vortexed and incubated at 25°C for 60-75 min, after which time the contents are rapidly vacuum-filtered and washed with about 12 ml/tube iced wash buffer (50 mM Tris, pH 7.0, 3 mM MgCl$_2$) through GF/B filters (Whatman) presoaked for at least 2h in 0.1% polyethyle- neimine. The radioactivity (dpm) retained on the filters was measured with a beta counter after soaking the filters for at least 12h in minivials containing 6-7 ml scintillation fluid. If the assay is set up in 96-place deep well plates, the filtration is over 96-place PEI-soaked unifilters, which were washed with 3 x 1 ml wash buffer, and dried in an oven at 55°C for 2h. The filter plates were counted in a TopCount (Packard) after adding 50 µl MS-20 scintillation fluid/well.

Functional Assays

[0052] The agonist activity of the compounds is measured by determining the degree to which the compounds receptor complex activates the binding of GTP to G-proteins to which the receptors are coupled. In the GTP binding assay, GTP [γ]35S is combined with test compounds and membranes from HEK-293S cells expressing the cloned human opioid receptors or from homogenised rat and mouse brain. Agonists stimulate GTP[γ]35S binding in these membranes. The EC$_{50}$ and E$_{max}$ values of compounds are determined from dose-response curves. Right shifts of the dose response curve by the delta antagonist naltirindole are performed to verify that agonist activity is mediated through delta receptors.

Procedure for rat brain GTP

[0053] Rat brain membranes are thawed at 37°C, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTPγS binding (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl$_2$, pH 7.4, Add fresh: 1 mM DTT, 0.1% BSA). 120µM GDP final is added membranes dilutions. The EC50 and Emax of compounds are evaluated from 10-point dose-response curves done in 300µl with the appropriate amount of membrane protein (20µg/well) and 100000-130000 dpm of GTPγS per well (0.11 -0.14nM). The basal and maximal stimulated binding are determined in absence and presence of 3µM SNC-80.

Data analysis

[0054] The specific binding (SB) was calculated as TB-NS, and the SB in the presence of various test compounds was expressed as percentage of control SB. Values of IC$_{50}$ and Hill coefficient ($n_H$) for ligands in displacing specifically bound radioligand were calculated from logit plots or curve fitting programs such as Ligand, GraphPad Prism, SigmaPlot, or ReceptorFit. Values of $K_i$ were calculated from the Cheng-Prussoff equation. Mean ± S.E.M. values of IC$_{50}$, $K_i$ and $n_H$ were reported for ligands tested in at least three displacement curves. Biological activity of the compounds of the present invention is indicated in Table 2.
Receptor Saturation Experiments

Radioligand $K_d$ values were determined by performing the binding assays on cell membranes with the appropriate radioligands at concentrations ranging from 0.2 to 5 times the estimated $K_d$ (up to 10 times if amounts of radioligand required are feasible). The specific radioligand binding was expressed as pmole/mg membrane protein. Values of $K_d$ and $B_{max}$ from individual experiments were obtained from nonlinear fits of specifically bound (B) vs. nM free (F) radioligand from individual according to a one-site model.

Determination Of Mechano-Alldynia Using Von Frey Testing

Testing was performed between 08:00 and 16:00h using the method described by Chaplan et al. (1994). Rats were placed in Plexiglas cages on top of a wire mesh bottom which allowed access to the paw, and were left to habituate for 10-15 min. The area tested was the mid-plantar left hind paw, avoiding the less sensitive foot pads. The paw was touched with a series of 8 Von Frey hairs with logarithmically incremental stiffness (0.41, 0.69, 1.20, 2.04, 3.63, 5.50, 8.51, and 15.14 grams; Stoelting, IL, USA). The von Frey hair was applied from underneath the mesh floor perpendicular to the plantar surface with sufficient force to cause a slight buckling against the paw, and held for approximately 6-8 seconds. A positive response was noted if the paw was sharply withdrawn. Flinching immediately upon removal of the hair was also considered a positive response. Ambulation was considered an ambiguous response, and in such cases the stimulus was repeated.

Testing Protocol

The animals were tested on postoperative day 1 for the FCA-treated group. The 50% withdrawal threshold was determined using the up-down method of Dixon (1980). Testing was started with the 2.04 g hair, in the middle of the series. Stimuli were always presented in a consecutive way, whether ascending or descending. In the absence of a paw withdrawal response to the initially selected hair, a stronger stimulus was presented; in the event of paw withdrawal, the next weaker stimulus was chosen. Optimal threshold calculation by this method requires 6 responses in the immediate vicinity of the 50% threshold, and counting of these 6 responses began when the first change in response occurred, e.g. the threshold was first crossed. In cases where thresholds fell outside the range of stimuli, values of 15.14 (normal sensitivity) or 0.41 (maximally alldynic) were respectively assigned. The resulting pattern of positive and negative responses was tabulated using the convention, X = no withdrawal; O = withdrawal, and the 50% withdrawal threshold was interpolated using the formula:

\[ 50% \text{ g threshold} = 10^{{X_f + k\delta}} / 10,000 \]

where $X_f =$ value of the last von Frey hair used (log units); $k =$ tabular value (from Chaplan et al. (1994)) for the pattern of positive / negative responses; and $\delta =$ mean difference between stimuli (log units). Here $\delta = 0.224$.

Von Frey thresholds were converted to percent of maximum possible effect (% MPE), according to Chaplan et al. 1994. The following equation was used to compute % MPE:

\[ \% \text{ MPE} = \frac{\text{Drug treated threshold (g)} - \text{alldynia threshold (g)}}{\text{Control threshold (g)} - \text{alldynia threshold (g)}} \times 100 \]

Administration Of Test Substance

Rats were injected (subcutaneously, intraperitoneally, intravenously or orally) with a test substance prior to von Frey testing, the time between administration of test compound and the von Frey test varied depending upon the nature
of the test compound.

Writhing Test

[0060] Acetic acid will bring abdominal contractions when administered intraperitoneally in mice. These will then extend their body in a typical pattern. When analgesic drugs are administered, this described movement is less frequently observed and the drug selected as a potential good candidate.

[0061] A complete and typical Writhing reflex is considered only when the following elements are present: the animal is not in movement; the lower back is slightly depressed; the plantar aspect of both paws is observable. In this assay, compounds of the present invention demonstrate significant inhibition of writhing responses after oral dosing of 1-100 μmol/kg.

(i) Solutions preparation

[0062] Acetic acid (AcOH): 120 μL of Acetic Acid is added to 19.88 ml of distilled water in order to obtain a final volume of 20 ml with a final concentration of 0.6% AcOH. The solution is then mixed (vortex) and ready for injection.

[0063] Compound (drug): Each compound is prepared and dissolved in the most suitable vehicle according to standard procedures.

(ii) Solutions administration

[0064] The compound (drug) is administered orally, intraperitoneally (i.p.), subcutaneously (s.c.) or intravenously (i.v.) at 10 ml/kg (considering the average mice body weight) 20, 30 or 40 minutes (according to the class of compound and its characteristics) prior to testing. When the compound is delivered centrally: Intraventricularly (i.c.v.) or intrathecally (i.t.) a volume of 5 μL is administered.

[0065] The AcOH is administered intraperitoneally (i.p.) in two sites at 10 ml/kg (considering the average mice body weight) immediately prior to testing.

(iii) Testing

[0066] The animal (mouse) is observed for a period of 20 minutes and the number of occasions (Writhing reflex) noted and compiled at the end of the experiment. Mice are kept in individual "shoe box" cages with contact bedding. A total of 4 mice are usually observed at the same time: one control and three doses of drug.

[0067] For the anxiety and anxiety-like indications, efficacy has been established in the geller-seifter conflict test in the rat.


Claims

1. A compound of the formula I
wherein
R¹ is selected from any one of

(i) phenyl;

(iv) furanyl

and
(vii) pyrrolyl

wherein each of phenyl, pyrrolyl, and furanyl may optionally and independently be substituted by 1 or 2 substituents selected from CF₃, methyl, chloro, fluoro, bromo, and iodo;

R² is independently selected from ethyl and isopropyl;
R³ is independently selected from hydrogen and fluoro; and
R⁴ is -NH₂;

or salts thereof or separate enantiomers and salts thereof.

2. A compound according to claim 1, wherein each of phenyl, pyrrolyl, and furanyl are substituted by 1 or 2 substituents selected from CF₃, methyl, iodo, bromo, fluoro or chloro.

3. A compound according to claim 1, wherein each of phenyl, pyrrolyl, and furanyl are substituted by 1 or 2 substituents selected from methyl.
4. A compound according to any of the preceding claims, in form of its hydrochloride, dihydrochloride, sulfate, tartrate, di trifluoroacetate or citrate salts.

5. A compound according to any of claims 1-4 for use in therapy.

6. Use of a compound according to formula I of claim 1 for the manufacture of a medicament for use in the treatment of pain, anxiety, or functional gastrointestinal disorders.

7. A pharmaceutical composition comprising a compound of the formula I according to claim 1 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

8. A compound according to any of claims 1-4 for the treatment of pain.

9. A compound according to any of claims 1-4 for the treatment of functional gastrointestinal disorders.

10. A compound according to any of claims 1-4 for the treatment of anxiety.
## DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 93/15062 A (WELLCOME FOUND [GB]) 5 August 1993 (1993-08-05) * pages 95-97; examples 32,33 * * page 1, lines 1-9 * * claims 1-26 *</td>
<td>1-10</td>
<td>INV. C07D295/14 A61K31/495 A61P1/00 A61P25/00</td>
</tr>
<tr>
<td></td>
<td>P,A WO 01/74805 A (ASTRAZENECA AB [SE]; BROWN WILLIAM [CA]; PLOBECK NIKLAS [CA]; WALPOLE) 11 October 2001 (2001-10-11) * page 1, lines 6-8 * * claims 1-17 *</td>
<td>1-10</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>WO 97/23466 A (ASTRA PHARMA INC [CA]; ASTRA AB [SE]; ROBERTS EDWARD [CA]; PLOBECK NIK) 3 July 1997 (1997-07-03) * page 1, lines 5-7 * * claims 1-16 *</td>
<td>1-10</td>
<td></td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims

**Place of search**  
Munich

**Date of completion of the search**  
2 February 2009

**Examiner**  
Marzi, Elena

**CATEGORY OF CITED DOCUMENTS**

- **T**: theory or principle underlying the invention
- **E**: earlier patent document, but published on, or after the filing date
- **D**: document cited in the application
- **L**: document cited for other reasons
- **X**: particularly relevant if taken alone
- **Y**: particularly relevant if combined with another document of the same category
- **A**: technological background
- **O**: non-written disclosure
- **F**: intermediate document
- **S**: member of the same patent family, corresponding document
This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 02.02.2009.

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

### Patent document cited in search report

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 9315062 A</td>
<td>05-08-1993</td>
<td>AT 237597 T</td>
<td>15-05-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 675928 B2</td>
<td>27-02-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 3457393 A</td>
<td>01-09-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2129046 A1</td>
<td>05-08-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69332882 D1</td>
<td>22-05-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69332882 T2</td>
<td>26-02-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 649414 T3</td>
<td>11-08-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2197152 T3</td>
<td>01-01-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 104582 A</td>
<td>30-10-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 7503247 T</td>
<td>06-04-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 246916 A</td>
<td>27-08-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 649414 T</td>
<td>30-09-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5658908 A</td>
<td>19-08-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9300717 A</td>
<td>02-08-1994</td>
</tr>
<tr>
<td>WO 0174805 A</td>
<td>11-10-2001</td>
<td>AT 297914 T</td>
<td>15-07-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4498301 A</td>
<td>15-10-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0109818 A</td>
<td>21-01-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2402705 A1</td>
<td>11-10-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1422266 A</td>
<td>04-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 20023287 A3</td>
<td>12-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 60111520 D1</td>
<td>21-07-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 60111520 T2</td>
<td>11-05-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EE 200200511 A</td>
<td>16-02-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 0300562 A2</td>
<td>28-08-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IS 6563 A</td>
<td>24-09-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003529597 T</td>
<td>07-10-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX PA02009758 A</td>
<td>27-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 20024776 A</td>
<td>03-12-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 521388 A</td>
<td>25-06-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 357812 A1</td>
<td>26-07-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 14262902 A3</td>
<td>02-05-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003139421 A1</td>
<td>24-07-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 200207381 A</td>
<td>15-12-2003</td>
</tr>
<tr>
<td>WO 9723466 A</td>
<td>03-07-1997</td>
<td>AU 715547 B2</td>
<td>03-02-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1216297 A</td>
<td>17-07-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9612204 A</td>
<td>13-07-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1209124 A</td>
<td>24-02-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 9801768 A3</td>
<td>16-09-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EE 9800194 A</td>
<td>15-12-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 9901304 A2</td>
<td>30-08-1999</td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82
This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EPO file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

02-02-2009

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 9723466 A</td>
<td>IS 4769 A</td>
<td>IS 4769 A</td>
<td>11-06-1998</td>
</tr>
<tr>
<td></td>
<td>JP 2000502679 T</td>
<td>JP 2000502679 T</td>
<td>07-03-2000</td>
</tr>
<tr>
<td></td>
<td>NO 982807 A</td>
<td>NO 982807 A</td>
<td>19-08-1998</td>
</tr>
<tr>
<td></td>
<td>NZ 324887 A</td>
<td>NZ 324887 A</td>
<td>28-01-2000</td>
</tr>
<tr>
<td></td>
<td>PL 327403 A1</td>
<td>PL 327403 A1</td>
<td>07-12-1998</td>
</tr>
<tr>
<td></td>
<td>RU 2194702 C2</td>
<td>RU 2194702 C2</td>
<td>20-12-2002</td>
</tr>
<tr>
<td></td>
<td>RU 2307833 C2</td>
<td>RU 2307833 C2</td>
<td>10-10-2007</td>
</tr>
<tr>
<td></td>
<td>SK 82298 A3</td>
<td>SK 82298 A3</td>
<td>04-11-1998</td>
</tr>
<tr>
<td></td>
<td>TR 9801180 T2</td>
<td>TR 9801180 T2</td>
<td>21-10-1998</td>
</tr>
<tr>
<td></td>
<td>TW 458971 B</td>
<td>TW 458971 B</td>
<td>11-10-2001</td>
</tr>
<tr>
<td></td>
<td>UA 71538 C2</td>
<td>UA 71538 C2</td>
<td>15-12-2004</td>
</tr>
<tr>
<td></td>
<td>US 6680321 B1</td>
<td>US 6680321 B1</td>
<td>20-01-2004</td>
</tr>
<tr>
<td></td>
<td>ZA 9610352 A</td>
<td>ZA 9610352 A</td>
<td>23-06-1997</td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description
